Ramoplanin oral

Drug Profile

Ramoplanin oral

Alternative Names: A 16686; A 16686A; MDL 62198; NTI-851; Ramoplanin

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Nanotherapeutics
  • Class Antiacnes; Antibacterials; Depsipeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vancomycin-resistant enterococcal infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Clostridium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Clostridium infections
  • Discontinued Vancomycin-resistant enterococcal infections

Most Recent Events

  • 25 Jun 2015 Phase-II development in Clostridium infections is ongoing in the US
  • 21 Oct 2010 Clinical development is ongoing in USA
  • 17 Dec 2009 Nanotherapeutics acquires rights to ramoplanin oral from Oscient Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top